載入...
Neoadjuvant Enzalutamide Prior to Prostatectomy
PURPOSE: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone...
Na minha lista:
發表在: | Clin Cancer Res |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
2016
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5570479/ https://ncbi.nlm.nih.gov/pubmed/28151719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1357 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|